This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Biogen (BIIB) Up as FDA Approves Alzheimer'S Drug Aducanumab
by Zacks Equity Research
FDA approves Biogen's (BIIB) Aduhelm (aducanumab), making it the first medicine to be approved to reduce the clinical decline associated with Alzheimer's disease.
Biotech ETFs Surge on Biogen's Alzheimer Drug Approval
by Sweta Killa
The approval for Biogen's Alzheimer's disease treatment has spread strong optimism, with many investors pulling in capital to this high growth and high beta sector.
3 Drug Stocks Rise as FDA Okays Biogen Alzheimer's Drug
by Kinjel Shah
FDA approves Biogen's (BIIB) Alzheimer's disease ("AD") drug, Aduhelm (aducanumab). Stocks of Eli Lilly (LLY), Cassava Sciences (SAVA) and Annovis Bio (ANVS) rise as they also have AD candidates in their portfolio.
Company News for Jun 8, 2021
by Zacks Equity Research
Companies in the news are: GIII, USCR, LMNL, BIIB
3 Top-Ranked Stocks to Buy Now on the Dip in June
by Benjamin Rains
We dive into three highly-ranked Zacks stocks with strong outlooks that are still trading well below their records even as the S&P 500 sits just off its highs...
Biogen's Alzheimer Drug Wins FDA Approval
by Mark Vickery
Biogen closed the day up 38% but had been up as much as 60% on the news, and this came after a brief halt in share trading.
Stock Market News for Jun 7, 2021
by Zacks Equity Research
Benchmarks closed in the green on Friday as lesser-than-expected job additions eased concerns that the Federal Reserve might tighten monetary policies soon
Biogen Inc. (BIIB) Stock Jumps 5%: Will It Continue to Soar?
by Zacks Equity Research
Biogen Inc. (BIIB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
AbbVie's (ABBV) Skyrizi Succeeds in Crohn's Maintenance Study
by Zacks Equity Research
AbbVie (ABBV) is focusing on label expansion of Skyrizi beyond plaque psoriasis. The drug achieves endoscopic response and clinical remission as maintenance treatment for Crohn's disease study.
Biotech Stock Roundup: MRNA COVID-19 Vaccine Update, Drug Approvals for ALKS, MYOV & More
by Zacks Equity Research
The biotech sector was in focus last week with pipeline and regulatory updates from Moderna (MRNA) and Alkermes (ALKS), among others.
PTC Therapeutics' (PTCT) PTC923 Gets Orphan Drug Tag in US & EU
by Zacks Equity Research
The FDA and the European Commission bestow Orphan Drug status to PTC Therapeutics' (PTCT) PTC923 for the treatment of hyperphenylalaninemia.
Zacks Industry Outlook Highlights: Regeneron, Gilead Sciences, Amgen, Biogen, BioNTech, Repligen and Ovid Therapeutics
by Zacks Equity Research
Zacks Industry Outlook Highlights: Regeneron, Gilead Sciences, Amgen, Biogen, BioNTech, Repligen and Ovid Therapeutics
3 Biotech Stocks to Keep an Eye On Amid the Coronavirus Mayhem
by Ekta Bagri
The focus on coronavirus treatments should maintain momentum for the volatile Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position BNTX, RGEN and OVID to perform well.
Biotech Stock Roundup: AGEN, SRPT Surge & BIIB, REGN Provide Pipeline Updates
by Zacks Equity Research
The biotech sector was in focus last week with pipeline and regulatory updates from Agenus (AGEN) and Sarepta (SRPT), among others.
Biogen (BIIB) Eye Disease Drug Misses Primary Goal in Study
by Zacks Equity Research
Biogen's (BIIB) rare, inherited retinal disease candidate, cotoretigene toliparvovec fails to meet the primary endpoint in a phase II/III study.
Biogen (BIIB) Decides to Acquire Phase II Stroke Candidate
by Zacks Equity Research
Biogen's (BIIB) decision to acquire TMS-007 is based on positive data from a phase IIa study, which met its primary safety objective with no incidence of symptomatic intracranial hemorrhage (sICH)
The Zacks Analyst Blog Highlights: Regeneron, Moderna, Minerva Neurosciences, Amgen and Biogen
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Regeneron, Moderna, Minerva Neurosciences, Amgen and Biogen
Biotech Stock Roundup: REGN's Q1 Earnings Update, MRNA's Vaccine Data & More
by Zacks Equity Research
The biotech sector was in focus last week with earnings updates from Regeneron (REGN) and Moderna (MRNA) and regulatory updates from Amgen, among others.
Biogen (BIIB) Signs New Gene Therapy Deal for CNS Disorders
by Zacks Equity Research
Biogen (BIIB) and Capsigen set to collaborate to make AAV capsids that have the potential to deliver transformative gene therapies for various CNS and neuromuscular disorders.
How Will Biotech ETFs React to These Q1 Earnings Releases?
by Sweta Jaiswal, FRM
Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.
Ionis (IONS) Q1 Loss Widens Year Over Year, Sales Miss
by Zacks Equity Research
Ionis (IONS) Q1 adjusted loss per share was wider than the year-ago figure. The company maintains its guidance for 2021.
Denali's (DNLI) Q1 Earnings Miss Estimates, Revenues Up Y/Y
by Zacks Equity Research
Denali (DNLI) posts a wider-than-expected loss in the first quarter of 2021 due to higher R&D costs.
Biotech Stock Roundup: BIIB, AMGN's Q1 Earnings Updates & Other Pipeline News
by Zacks Equity Research
The biotech sector was in focus last week with earnings updates form Biogen (BIIB) and Amgen (AMGN), and regulatory updates from Bristol Myers (BMY), among others.
Pharma/Biotech Stocks' Q1 Earnings Queued for Apr 29: MRK, BMY & More
by Zacks Equity Research
Let us take a look at what is in store for some of the pharma/biotech stocks, which are scheduled to report on Apr 29.
Alzheimer's Disease: 5 Stocks on Biotech Radars
by Kevin Cook
While Biogen rides a big-cap rollercoaster, a few small players are creating better trading opps.